PATENT CLAIM ANALYSIS

Application Number: 16020363
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-11
Patent Classification: ["424", "094600"]

Abstract:
Provided is a use of a recombinant human calcineurin B subunit (rhCNB) in the preparation of a medicine for killing and/or inhibiting the gastric cancer.

Claim (Index 10):
The method according to  claim 1 , wherein the rhCNB or its functional variant or fragment is administrated via intravenous injection once daily for 15 consecutive days, at a dose of 10, 20, 40 mg/kg or at a first dose of 10 mg/kg, followed by doubling the preceding dose every 3 days, which are 10 mg/kg, 20 mg/kg, 40 mg/kg, 80 mg/kg, and 160 mg/kg successively.

Metadata:
- Claim Count in Document: 7.0
- Percentile: 94.0
- Lexical Diversity: 1.16667
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['10600152', '15684168', '13280974', '14073659', '15268298']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6285574718863202
- 35 USC 102 Novelty (BERT): 0.5020602346073695
- Combined Prediction Score: 0.6159077481584252
- Mean Citation Score: 185.662514
- Max Citation Score: 189.60634
- Similarity Product: 115.39453540779112

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test